NCT01369329

Who might be able to join this trial:

• You have been diagnosed with Crohn's disease for at least 3 months, affecting your colon, small intestine, or both, confirmed at some point by imaging, tissue testing, or a camera examination of the gut.
• Your Crohn's disease is currently active, based on a specific scoring system that measures disease activity (confirm with trial site for exact score requirements).
• You have previously tried one of these medications for Crohn's disease — infliximab, adalimumab, or certolizumab pegol — at the standard approved dose, and it never worked for you in the first place.
• Or you tried one of those medications and it worked at first but then stopped working over time.
• Or you tried one of those medications but had to stop because you could not tolerate it.
• Your recent blood or lab test results fall within the ranges required by the study.

Who may not be able to join:

• You have had any type of bowel surgery within the last 6 months.
• You are pregnant, planning to become pregnant, or (if male) planning to father a child while in the study or within 20 weeks after receiving the study treatment.
• You received infliximab, adalimumab, or certolizumab pegol within 8 weeks before the study drug would first be given to you.
• You have certain serious complications from Crohn's disease that would make it difficult to measure how well the study drug is working (confirm with trial site for specifics).
• You have a history of, or currently have, a long-term or repeatedly occurring infectious disease.
• You have previously received a biologic medication that targets specific parts of the immune system known as IL-12 or IL-23, such as ustekinumab or briakinumab.

Important: Always verify eligibility with the trial site directly before applying.